Australia's Saluda Medical rises as FDA approves pain-treatment device for US market

Saluda Medical

30/06/2026 03:19

** Shares of Australia's Saluda Medical SLD.AX rise as much as 24.4% to A$0.510, hitting their highest level since May 15
** Stock on track for its best day since June 2, if gains hold          
** The medical device firm says the U.S. Food and Drug Administration (FDA) has approved its CAP24 paddle lead
** Adds that approval allows the product to be marketed and sold in the U.S.
** Paddle lead is a medical device used in Spinal Cord Stimulation to treat chronic back, arm, or leg pain
** Stock down over 65% this year, including the day's move

 (Reporting by Rajasik Mukherjee in Bengaluru)
 ((Rajasik.Mukherjee@thomsonreuters.com))